Stoke Therapeutics, Inc. (STOK): Cash & Equivalents
$84.22M
As of 2025-12-31
$110.00M
As of 2026-06-30
-9.5%
3-year compound annual growth
-21.8%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $84.22M | -34.2% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $127.98M | -33.1% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $191.44M | +68.6% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $113.56M | -21.6% | 2024-03-25, Balance as of period end |
| 2021-12-31 | $144.90M | -49.6% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $287.31M | +29.1% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $222.47M | +111.1% | 2021-03-09, Balance as of period end |
| 2018-12-31 | $105.40M | n/a | 2020-03-23, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $84.22M | -34.2% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $216.89M | -32.7% |
| Lifevantage Corp (LFVN) | 2025-06-30 | $20.20M | +19.6% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $54.30M | -39.1% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $250.49M | +633.8% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $129.97M | -56.3% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $134.93M | -12.4% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $134.66M | +11.3% |
| Liquidia Corp (LQDA) | 2025-12-31 | $190.68M | +8.0% |
Compare STOK, MRVI, LFVN, RYTM side by side · Screen every company in Pharmaceutical Preparations ↗